Northern Trust Corp Lowers Holdings in LENSAR, Inc. (NASDAQ:LNSR)

Northern Trust Corp decreased its stake in shares of LENSAR, Inc. (NASDAQ:LNSR) by 28.3% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 20,046 shares of the company’s stock after selling 7,922 shares during the period. Northern Trust Corp owned 0.17% of LENSAR worth $179,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of LNSR. Bailard Inc. acquired a new position in LENSAR in the fourth quarter valued at $181,000. Atria Investments Inc raised its holdings in shares of LENSAR by 28.2% in the 4th quarter. Atria Investments Inc now owns 26,055 shares of the company’s stock worth $233,000 after purchasing an additional 5,729 shares during the period. Essex Investment Management Co. LLC lifted its stake in shares of LENSAR by 18.3% in the 4th quarter. Essex Investment Management Co. LLC now owns 39,890 shares of the company’s stock valued at $357,000 after purchasing an additional 6,184 shares in the last quarter. Brandes Investment Partners LP grew its holdings in shares of LENSAR by 10.4% during the 4th quarter. Brandes Investment Partners LP now owns 489,318 shares of the company’s stock worth $4,375,000 after purchasing an additional 45,920 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of LENSAR by 5.6% during the 4th quarter. Geode Capital Management LLC now owns 106,058 shares of the company’s stock worth $948,000 after purchasing an additional 5,627 shares during the period. Hedge funds and other institutional investors own 40.15% of the company’s stock.

LENSAR Stock Down 0.1%

Shares of NASDAQ:LNSR opened at $13.52 on Tuesday. The company has a market capitalization of $159.43 million, a price-to-earnings ratio of -9.26 and a beta of 0.56. The company has a 50 day moving average of $13.84 and a two-hundred day moving average of $11.36. LENSAR, Inc. has a 52-week low of $3.50 and a 52-week high of $17.31.

LENSAR (NASDAQ:LNSR) last released its quarterly earnings results on Thursday, May 8th. The company reported ($2.32) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.16) by ($2.16). The firm had revenue of $11.53 million for the quarter, compared to analysts’ expectations of $13.40 million. LENSAR had a negative return on equity of 49.02% and a negative net margin of 34.03%.

Analyst Ratings Changes

LNSR has been the subject of several recent research reports. Lake Street Capital reiterated a “hold” rating and issued a $15.00 price target (down from $16.00) on shares of LENSAR in a report on Monday, March 24th. BTIG Research downgraded LENSAR from a “strong-buy” rating to a “hold” rating in a research report on Monday, March 24th.

LENSAR Profile

LENSAR, Inc, a commercial-stage medical device company, focuses on designing, developing, and marketing a femtosecond laser system for the treatment of cataracts and the management of pre-existing or surgically induced corneal astigmatism. It offers LENSAR Laser System that incorporates a range of proprietary technologies designed to assist the surgeon in obtaining visual outcomes, efficiency, and reproducibility by providing imaging, procedure planning, design, and precision.